Immuron Limited Warrants
IMRNW
NASDAQ Capital Market0.09
USD
+0.01
- -
CIK
0001660046
ISIN
USQ4867H2235
CUSIP
Q4867H223
Return %
Stock
S&P500
1Y
- -
26.84
3Y
-50.38
77.03
5Y
-73.69
80.55
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- None
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- United States of America
- IPO Date
- Jun 9, 2017
- CIK
- 0001660046
- Similar Companies
- Business
- Immuron Limited Warrants (IMRNW) represent warrants to purchase shares of Immuron Limited, an Australian biotechnology company focused on developing and commercializing oral immunoglobulins for treating infectious diseases and gastrointestinal conditions in humans and animals. Immuron produces specialized plasma-derived protein therapeutics, including its flagship product TravelRite IMM55, an oral immunoglobulin formulation designed to prevent travelers' diarrhea caused by ETEC bacteria; Immuron Protect IMM124E, targeting non-alcoholic steatohepatitis (NASH) and liver inflammation through elevated levels of specific antibodies; and other polyclonal antibody products derived from hyper-immune bovine colostrum, such as those for preventing cryptosporidiosis and supporting gut health in livestock. The company operates primarily in the biopharmaceutical sector, serving human health markets with a focus on gastrointestinal and infectious disease prevention, as well as veterinary applications; its products target consumers in travel medicine, patients with liver diseases, and agricultural sectors. Founded in 1994 and headquartered in Melbourne, Australia, Immuron conducts research, manufacturing, and clinical development across Australia and the United States, with distribution in select international markets including North America and Asia. In recent developments within the last two years, Immuron announced positive Phase II clinical trial results for its NASH candidate in 2024, strengthening its pipeline; entered a strategic manufacturing partnership with a U.S.-based contract development organization to scale production of its oral immunoglobulins; and secured additional funding through warrant exercises tied to IMRNW, supporting expanded clinical programs without major acquisitions or name changes.